Cohance Lifesciences Limited has received a disclosure under SEBI takeover regulations from Jasti Property and Equity Holdings Private Limited, acting as sole trustee of Jasti Family Trust, regarding changes in shareholding patterns. The latest disclosure, dated February 24, 2026, was submitted to both NSE and BSE pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Latest Transaction Overview

The Jasti Family Trust and its persons acting in concert (PAC) have maintained their combined shareholding in Cohance Lifesciences at 6.36% of the total share capital through internal restructuring. The transaction involved 77,00,000 shares, representing 2.01% of the company's total voting capital, executed through inter-se transfer via block deals on February 23, 2026.

Internal Shareholding Restructuring

While the overall group holding remained unchanged, there was significant internal restructuring among the entities within the Jasti Family Trust group:

Primary Entity Changes

• Jasti Property and Equity Holdings Private Limited (as sole trustee): Reduced from 1,73,16,009 shares (4.53%) to 96,16,009 shares (2.52%)
• Jasub Property Holdings LLP (PAC): Increased from 70,00,000 shares (1.83%) to 1,47,00,000 shares (3.84%)

Other PAC Members

• Mrs. Venkata Subbamma Jasti: 6,000 shares (negligible percentage)
• Mr. Venkateswarlu Jasti: 2,000 shares (negligible percentage)
• Mrs. Sudharani Jasti: 2,000 shares (negligible percentage)

Transaction Details

Company Capital Structure

The company's equity share capital remained unchanged at 38,25,67,140 shares, while the total diluted share capital stands at 39,22,07,995 shares, assuming full conversion of outstanding convertible securities and warrants.

Regulatory Compliance

The disclosure confirms that the acquirer does not belong to the promoter or promoter group of Cohance Lifesciences Limited. The transaction was conducted in compliance with SEBI regulations, with proper notifications submitted to both stock exchanges where the company's shares are listed - BSE Limited and National Stock Exchange of India Limited.

The disclosure was signed by Venkateswarlu Jasti on behalf of Jasti Property and Equity Holdings Private Limited in its capacity as sole trustee of Jasti Family Trust, with copies provided to the company secretary of Cohance Lifesciences Limited.

JASUB Property Holdings LLP has acquired a significant stake in Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, through a substantial share acquisition completed on February 18, 2026. The acquisition has been disclosed under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Acquisition Details

The transaction involved the purchase of 70,00,000 equity shares, representing 1.83% of the total share capital and 1.78% of the diluted share capital of Cohance Lifesciences. The acquisition was executed through inter-se transfer via block deals, marking JASUB Property Holdings LLP's entry as a shareholder in the pharmaceutical company.

Shareholding Pattern Analysis

Prior to this acquisition, JASUB Property Holdings LLP held no shares in Cohance Lifesciences. However, the company operates in concert with several related entities that already held substantial positions in the target company.

Pre-Acquisition Holdings of Persons Acting in Concert

Post-Acquisition Position

Following the completion of this transaction, the combined holding of JASUB Property Holdings LLP and its persons acting in concert stands at 2,43,26,009 shares, representing 6.36% of the total share capital and 6.20% of the diluted share capital.

Current Shareholding Structure

Company Information

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is listed on both BSE Limited and National Stock Exchange of India Limited. The company's total equity share capital stands at 38,25,67,140 shares, while the diluted share capital is 39,22,07,995 shares, accounting for potential conversion of outstanding convertible securities.

Regulatory Compliance

The disclosure was filed by V. Lakshmana Rao, Designated Partner of JASUB Property Holdings LLP, in compliance with SEBI regulations governing substantial acquisitions. The acquirer has confirmed that it does not belong to the promoter or promoter group of Cohance Lifesciences Limited. The filing also notes that out of the previously held shares by persons acting in concert, 8,76,948 shares were sold in the open market between September 8, 2025, and January 8, 2026.